AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27253214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation (GP)
Number of subjects: 85
Study 27253214 — intervention group
Group type: COMPARATOR
Intervention: Individual psychoeducation (IP)
Number of subjects: 85
Study 25354581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1xH5N1‐AS
Number of subjects: 160
Study 25354581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2xH5N1‐AS
Number of subjects: 160
Study 25354581 — intervention group
Group type: COMPARATOR
Intervention: 1xH5N1
Number of subjects: 160
Study 25354581 — intervention group
Group type: COMPARATOR
Intervention: 2xH5N1
Number of subjects: 160
Study 25354581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1xH5N1‐AS (neutralising antibodies)
Number of subjects: 160
Study 25354581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2xH5N1‐AS (neutralising antibodies)
Number of subjects: 160
Study 22565360 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity assistance during sit-to-stand (STS) task
Number of subjects: 28
Study 22565360 — intervention group
Group type: EXPERIMENTAL
Intervention: No upper extremity assistance during sit-to-stand (STS) task
Number of subjects: 28
Study 20392868 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTSH
Number of subjects: 88
Study 20392868 — intervention group
Group type: COMPARATOR
Intervention: hypothyroid
Number of subjects: 88
Study 17555530 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral risedronate (35 mg) with vitamin D and calcium
Number of subjects: 84
Study 17555530 — intervention group
Group type: COMPARATOR
Intervention: Control group (vitamin D and calcium only)
Number of subjects: 84
Study 15703503 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 0
Study 15703503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12432190 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5 days treatment)
Number of subjects: 13
Study 12432190 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (14 days treatment)
Number of subjects: 13
Study 12432190 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 13
Study 10080586 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-based neoadjuvant chemotherapy
Number of subjects: 372
Study 8551959 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (AB) alone
Number of subjects: 20
Study 8551959 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (AB) + Itraconazole (IZ)
Number of subjects: 20
Study 1776591 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethiazole (384 mg)
Number of subjects: 9
Study 1776591 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (10 mg)
Number of subjects: 9
Study 1776591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7030645 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcinonide cream 0.1 percent
Number of subjects: 29
Study 7030645 — intervention group
Group type: COMPARATOR
Intervention: Halcinonide cream 0.1 percent
Number of subjects: 29
Study 31347002 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple puncture treatment (6 times per week for 4 weeks)
Number of subjects: 64
Study 31347002 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (300‐600 mg per day for at least 1 month)
Number of subjects: 64
Study 29566104 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus Letrozole (10 mg/d + 2.5 mg/d) in first-line treatment
Number of subjects: 202
Study 29566104 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus Exemestane (10 mg/d + 25 mg/d) in second-line treatment
Number of subjects: 202
Study 29566104 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in first-line treatment
Number of subjects: 202
Study 29566104 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in second-line treatment
Number of subjects: 202
Study 29566104 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality during the study
Number of subjects: 202
Study 27900992 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved intermittent‐clamped drainage (ICD)
Number of subjects: 156
Study 27900992 — intervention group
Group type: COMPARATOR
Intervention: Continuous negative pressure drainage (CNPD)
Number of subjects: 156
Study 27900992 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 156
Study 24860157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation strategy to achieve E'(CO₂) values of 40‐42 mm Hg
Number of subjects: 70
Study 24860157 — intervention group
Group type: COMPARATOR
Intervention: Ventilation strategy to achieve E'(CO₂) values of 30‐32 mm Hg
Number of subjects: 70
Study 22555350 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive oral care protocol (tongue scraping, electric toothbrushing, moisturizing)
Number of subjects: 56
Study 22555350 — intervention group
Group type: COMPARATOR
Intervention: Standard oral care protocol (manual toothbrushing)
Number of subjects: 56
Study 20681276 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingko biloba Tablet (GBT)
Number of subjects: 84
Study 20681276 — intervention group
Group type: COMPARATOR
Intervention: Control group (furosemide, spironolactone, and perindopril without GBT)
Number of subjects: 84
Study 16949722 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic method of presenting information
Number of subjects: 150
Study 16949722 — intervention group
Group type: EXPERIMENTAL
Intervention: Written method of presenting information
Number of subjects: 150
Study 16949722 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive method of presenting information
Number of subjects: 150
Study 16275189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine (50 to 70 mug/kg/min)
Number of subjects: 30
Study 16275189 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 30
Study 12358999 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers in the target school
Number of subjects: 136
Study 12358999 — intervention group
Group type: COMPARATOR
Intervention: Teachers in the control school
Number of subjects: 136
Study 12358999 — intervention group
Group type: COMPARATOR
Intervention: Students
Number of subjects: 136
Study 12358999 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers with dry and crusty nasal mucosa
Number of subjects: 136
Study 12358999 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic and non-atopic subjects
Number of subjects: 136
Study 10500058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg once daily)
Number of subjects: 742
Study 10500058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg once daily)
Number of subjects: 742
Study 10500058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg 3 times daily)
Number of subjects: 742
Study 10500058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study 8953672 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g bolus dose)
Number of subjects: 146
Study 8953672 — intervention group
Group type: COMPARATOR
Intervention: Lymecycline (10-day course of 300 mg twice daily)
Number of subjects: 146
Study 8953672 — intervention group
Group type: COMPARATOR
Intervention: Lymecycline
Number of subjects: 146
Study 8953672 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 146
Study 1834805 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis (tissue plasminogen activator or streptokinase)
Number of subjects: 0
Study 1834805 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis and aspirin combined
Number of subjects: 0
Study 1834805 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 0
Study 7046098 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg daily
Number of subjects: 60
Study 7046098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at night
Number of subjects: 60
Study 7046098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29908054 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored adaptation of the Diabetes Prevention Program
Number of subjects: 0
Study 29908054 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25986943 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day quadruple anti-H. pylori treatment with a single dosage of omeprazole and bismuth
Number of subjects: 184786
Study 25986943 — intervention group
Group type: COMPARATOR
Intervention: Lookalike placebos with a single dosage of omeprazole and bismuth
Number of subjects: 184786
Study 23587468 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome met (39% of patients, 30/76)
Number of subjects: 76
Study 21848573 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I workshops (experimental group)
Number of subjects: 151
Study 21848573 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 151
Study 20586002 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 microg antigen with 50% of the standard MF59 dose (group A)
Number of subjects: 123
Study 20586002 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 microg antigen and 100% standard MF59 dose (group B)
Number of subjects: 123
Study 17354223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) administration of yttrium‐90‐labeled murine monoclonal antibody HMFG1 ((90)Y‐muHMFG1)
Number of subjects: 447
Study 17354223 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 447
Study 15689218 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Dead Sea salt solution (Mavena(R) Dermaline Mg(46) Dead Sea salt) for 15 minutes
Number of subjects: 0
Study 15689218 — intervention group
Group type: COMPARATOR
Intervention: Tap water (control)
Number of subjects: 0
Study 15689218 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Dead Sea salt solution
Number of subjects: 0
Study 12196422 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 79
Study 12196422 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg
Number of subjects: 79
Study 12196422 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nateglinide and troglitazone
Number of subjects: 79
Study 12196422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 9492967 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing strategies
Number of subjects: 0
Study 9492967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking recruitment process yield
Number of subjects: 0
Study 8129216 — intervention group
Group type: EXPERIMENTAL
Intervention: Open challenge testing
Number of subjects: 0
Study 8129216 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-blind testing
Number of subjects: 0
Study 8129216 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled oral challenge test
Number of subjects: 0
Study 8129216 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination-challenge test
Number of subjects: 0
Study 2774259 — intervention group
Group type: EXPERIMENTAL
Intervention: liquids, up to 5 ml/kg + placebo (glucose water 0.2 ml/kg)
Number of subjects: 88
Study 2774259 — intervention group
Group type: EXPERIMENTAL
Intervention: liquids, up to 5 ml/kg + ranitidine 2 mg/kg in glucose water 0.2 ml/kg
Number of subjects: 88
Study 2774259 — intervention group
Group type: COMPARATOR
Intervention: placebo only
Number of subjects: 88
Study 2774259 — intervention group
Group type: COMPARATOR
Intervention: ranitidine only
Number of subjects: 88
Study 4645896 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung perfusion scanning using radioactive particles
Number of subjects: 6
Study 30880075 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitutional repairs (dorsal grafts)
Number of subjects: 2098
Study 30880075 — intervention group
Group type: EXPERIMENTAL
Intervention: Excisional repairs
Number of subjects: 2098
Study 30880075 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage dorsal repairs
Number of subjects: 2098
Study 27919361 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined carbohydrate (CARB) diet for 6 weeks
Number of subjects: 0
Study 27919361 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA) diet for 6 weeks
Number of subjects: 0
Study 27919361 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SAFA) diet for 6 weeks
Number of subjects: 0
Study 27919361 — intervention group
Group type: COMPARATOR
Intervention: Control (SAFA)
Number of subjects: 0
Study 24924587 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 614
Study 24924587 — intervention group
Group type: COMPARATOR
Intervention: No Digoxin
Number of subjects: 614
Study 22591460 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery within an enhanced recovery programme
Number of subjects: 202
Study 22591460 — intervention group
Group type: COMPARATOR
Intervention: Conventional open resection of colorectal cancer within an enhanced recovery programme
Number of subjects: 202
Study 20044673 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip resurfacing with Metasul articulation and titanium plasma-sprayed coating
Number of subjects: 0
Study 20044673 — intervention group
Group type: COMPARATOR
Intervention: Total hip replacement with titanium CLS/Spotorno femoral components and titanium AlloFit acetabular components
Number of subjects: 0
Study 19056791 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols
Number of subjects: 70
Study 19056791 — intervention group
Group type: EXPERIMENTAL
Intervention: Publications
Number of subjects: 70
Study 16710349 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin
Number of subjects: 86
Study 16710349 — intervention group
Group type: COMPARATOR
Intervention: 30 g cholestyramine
Number of subjects: 86
Study 12610252 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perceived coercion scores during hospitalization and at follow-ups
Number of subjects: 117
Study 12610252 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perceived coercion scores
Number of subjects: 117
Study 11127083 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 0
Study 11127083 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 0
Study 11127083 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 0
Study 11127083 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid (VPA)
Number of subjects: 0
Study 8973074 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year family counseling program (10 times/year)
Number of subjects: 160
Study 8973074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 160
Study 8199503 — intervention group
Group type: EXPERIMENTAL
Intervention: Requiring signed consent for influenza vaccination
Number of subjects: 0
Study 8199503 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminder letters and information packages in patients' charts
Number of subjects: 0
Study 3373260 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour infusion of weekly fluorouracil (5-FU) at a dose of 750 mg/m2 incrementally increased to 3,400 mg/m2
Number of subjects: 52
Study 3373260 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour infusion of weekly fluorouracil (5-FU) plus N-(phosphonacetyl)-L-aspartic acid (PALA) administered as an IV bolus over 15 minutes at a fixed dose of 250 mg/m2
Number of subjects: 52
Study 30912860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 22
Study 30912860 — intervention group
Group type: COMPARATOR
Intervention: Monitor-Only (MO)
Number of subjects: 22
Study 30912860 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) and Monitor-Only (MO)
Number of subjects: 22
Study 29173854 — intervention group
Group type: EXPERIMENTAL
Intervention: BioCosmetic (Forestadent, 0.017 in)
Number of subjects: 150
Study 29173854 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanol (Forestadent, 0.016 in)
Number of subjects: 150
Study 29173854 — intervention group
Group type: EXPERIMENTAL
Intervention: TP Aesthetic (TP Orthodontics, 0.014 in)
Number of subjects: 150
Study 29173854 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Tone (Ortho Organizers, 0.016 in)
Number of subjects: 150
Study 29173854 — intervention group
Group type: EXPERIMENTAL
Intervention: BioCosmetic
Number of subjects: 150
Study 29173854 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanol
Number of subjects: 150
Study 29173854 — intervention group
Group type: EXPERIMENTAL
Intervention: TP Aesthetic
Number of subjects: 150
Study 29173854 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Tone
Number of subjects: 150
Study 26212672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% saline
Number of subjects: 151
Study 26212672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% saline
Number of subjects: 151
Study 26212672 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 151
Study 23315907 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotropic Index (CI) < 0.6
Number of subjects: 1118
Study 23315907 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotropic Index (CI)
Number of subjects: 1118
Study 21318931 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based HIV intervention (two 60-minute sessions)
Number of subjects: 135
Study 21318931 — intervention group
Group type: COMPARATOR
Intervention: Control session of general health information
Number of subjects: 135
Study 19690066 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 8 mg daily for 16 weeks
Number of subjects: 13
Study 19690066 — intervention group
Group type: COMPARATOR
Intervention: placebo for 16 weeks
Number of subjects: 13
Study 19690066 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 13
Study 17125718 — intervention group
Group type: EXPERIMENTAL
Intervention: Right radial approach
Number of subjects: 351
Study 17125718 — intervention group
Group type: COMPARATOR
Intervention: Left radial approach
Number of subjects: 351
Study 15574090 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 24
Study 15574090 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 24
Study 11585270 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: Ondansetron 8 mg i.v. at 4-h intervals plus dexamethasone 20 mg i.v. from the start of CT, followed by dexamethasone 5 mg i.v. every 12 h until CT was complete.
Number of subjects: 400
Study 11585270 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: Same treatment as arm A but with ondansetron 8 mg i.v. given at 24-h intervals.
Number of subjects: 400
Study 9101974 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 0
Study 9101974 — intervention group
Group type: COMPARATOR
Intervention: Excellent hygienic conditions and advanced surgical techniques
Number of subjects: 0
Study 1712952 — intervention group
Group type: EXPERIMENTAL
Intervention: Day case management
Number of subjects: 50
Study 1712952 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-patient management
Number of subjects: 50
Study 6500902 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprine 8 mg daily
Number of subjects: 25
Study 6500902 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprine (various rising doses)
Number of subjects: 25
Study 31413233 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intake of Hericium erinaceus for 12 weeks
Number of subjects: 0
Study 31413233 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 30589045 — intervention group
Group type: EXPERIMENTAL
Intervention: OxyContin 10 mg orally, adjusted according to pain relief
Number of subjects: 60
Study 30589045 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized nursing intervention
Number of subjects: 60
Study 30589045 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 26511964 — intervention group
Group type: EXPERIMENTAL
Intervention: IminoNorm® (mulberry leaf extract)
Number of subjects: 40
Study 26511964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24157459 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Number of subjects: 50
Study 24157459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24157459 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 50
Study 20884888 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 29
Study 19136369 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (50, 100, or 200 mg)
Number of subjects: 309
Study 19136369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 19136369 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 309
Study 17188080 — intervention group
Group type: COMPARATOR
Intervention: Standard D2 lymphadenectomy
Number of subjects: 275
Study 17188080 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended D2+ lymphadenectomy
Number of subjects: 275
Study 15077258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 15077258 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (PE)
Number of subjects: 0
Study 11424316 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (200 mg b.i.d.), amoxicillin (500 mg q.i.d.), and lansoprazole (30 mg b.i.d.) for 5 days
Number of subjects: 90
Study 11424316 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (200 mg b.i.d.), amoxicillin (500 mg q.i.d.), and lansoprazole (30 mg b.i.d.) for 7 days
Number of subjects: 90
Study 9663361 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide administered topically TID
Number of subjects: 311
Study 9663361 — intervention group
Group type: COMPARATOR
Intervention: 0.5% betaxolol administered topically BID plus placebo administered topically QD
Number of subjects: 311
Study 9663361 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide
Number of subjects: 311